Jame Abraham, MD, on HER2-Positive Breast Cancer: Results of the BCIRG-006 Study
2015 San Antonio Breast Cancer Symposium
Jame Abraham, MD, of the Cleveland Clinic, discusses the 10-year follow-up of this trial, and the long-term benefit and safety of adding trastuzumab to the adjuvant treatment of HER2-positive early breast cancer (Abstract S5-04).
Clifford A. Hudis, MD, and William J. Gradishar, MD
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and William J. Gradishar, MD, of the Lurie Comprehensive Cancer Center, discuss the most important papers and results at this year's San Antonio Breast Cancer Symposium.
Michael Gnant, MD
Michael Gnant, MD, of the Medical University of Vienna, discusses a study in which denosumab was added to adjuvant aromatase inhibitor therapy to improve disease-free survival in postmenopausal patients with early-stage, hormone receptor–positive breast cancer (Abstract S2-02).
Andrew Seidman, MD, and Ruth M. O’Regan, MD
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Ruth M. O’Regan, MD, of the University of Wisconsin, review practice-changing research in 2015 that was focused on early-stage breast cancer.
Clifford A. Hudis, MD, and Julia R. White, MD
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Julia R. White, MD, of Ohio State University Comprehensive Cancer Center, discuss a meta-analysis on efficacy and safety of hypofractionated radiotherapy for the treatment of early-stage breast cancer (Abstract P3-12-15).
Hans Wildiers, MD, PhD
Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously treated HER2-positive metastatic breast cancer (Abstract S5-05).